Please assess the completion status of the following clinical trial:

Trial Title: Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of advanced NSCLC not amenable to curative treatment. Participants enrolling in Part 2 of the study must have the above stated diagnosis of NSCLC that is also of nonsquamous histology.~* no prior systemic therapies \[chemotherapy, et cetera (etc.)\] or pleurodesis with chemotherapy for this disease~* prior radiotherapy is allowed but must be completed at least 2 weeks before study enrollment and participant must be recovered from the acute toxic effects~* have a good performance status~* participant must sign an informed consent document~Exclusion Criteria:~* participant had myocardial infarction occurring less than 6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications~* participant is unable to swallow tablets~* participant is taking a certain medicine to control seizure activity, called enzyme inducing antiepileptic drugs and is not able to stop taking the medicine prior to enrolling in the study~* participant is unable to interrupt aspirin and/or other anti-inflammatory agents~* participant is unwilling or unable to take vitamin supplementation (folic acid and vitamin B12) or medications to prevent side effects

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzastaurin + Pemetrexed + Cisplatin (Type: EXPERIMENTAL): None
- Placebo + Pemetrexed + Cisplatin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).